Physician profile

Jennifer Sacks

Pediatrics · North Syracuse, NY

NPI 1548404932

$641.62

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$259.54

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi Pasteur INC. $158.40 2019-2023
Pfizer INC. $121.00 2019-2024
Sobi, INC $82.59 2019-2023
Sanofi-Aventis U.S. LLC $76.86 2024
Kaleo, INC. $67.16 2020-2022
Merck Sharp & Dohme LLC $43.49 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $26.85 2019-2020
Glaxosmithkline, LLC. $18.94 2022
Corium, LLC $18.11 2023 Azstarys
Mission Pharmacal Company $15.02 2019
Exeltis, USA INC. $13.20 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jennifer Sacks

$641.62

in general payments reported 2019-2025

Years
2019-2024
Top company
Sanofi Pasteur INC.

https://glasscript.com/doctor/720787/jennifer-sacks

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.